Best Cardiac and Vascular Disorders Companies in Australia
The 39 best Cardiac and Vascular Disorders companies in Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Heart Ware.
Ranked: Best Cardiac and Vascular Disorders companies in Australia
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Heart Ware Implantable ventricular assist devices | $55M | 204 mo ago | Late Stage | Doug Godshall President & CEO | 1995 | — | — | — |
| 2 | Infensa Developer of peptide drugs for cardiovascular disorders | $16M | 50 mo ago | Series B | Mark Smythe Chief Executive Officer | 2021 | — | — | — |
| 3 | HD Medical Group Developer of stethoscopes with integrated phonocardiogram visual display | $5M | 91 mo ago | Series A | — | 2005 | — | 7 patents Sealed vaginal speculums and molded thermoplastic foam medical components for gynecological use. | — |
| 4 | WearOptimo Developer of wearable sensor technology for real-time personal health monitoring | $5M | 45 mo ago | Series A | Mark Kendall Founder & Chief Executive Officer | 2018 | WordPressMySQLPHP+23 | — | — |
| 5 | CliniCloud Developing smart stethoscope and thermometer kit | $5M | 131 mo ago | Deadpooled | — | 2012 | — | — | — |
| 6 | Regeneus Cell based therapies with a focus on osteoarthritis and other musculoskeletal disorders, oncology and… | $2M | 96 mo ago | Public | — | 2007 | — | 6 patents Adipose-derived cell suspension therapies and processing devices for regenerative medicine | — |
| 7 | Semacare Remote vital signs monitor with Bluetooth connctivity | $1M | 74 mo ago | Series A | Roger Luo Co-Founder & COO | 2014 | — | — | — |
| 8 | Andi Provider of wearable device and app for monitoring body vitals parameters | $600K | 53 mo ago | Deadpooled | — | 2019 | — | — | — |
| 9 | National Cardiac Monitoring Develops a wearable device for cardiac monitoring | $580K | 87 mo ago | Acqui-Hired | Paul Diperna CEO | 2011 | — | — | — |
Top 11 Cardiac and Vascular Disorders companies in Australia
#1
Series A · Brisbane, Queensland · founded 2018 · 35 employees$5Mraised▾
Developer of wearable sensor technology for real-time personal health monitoring. The company focuses on creating microwearable sensors that capture data from the body's bio-signals. These sensors allow for the detection and treatment of health issues. The initial product is a hydration microwearable sensor designed for continuous monitoring. The technology aims to improve physical and mental performance through advanced machine learning.
- Nov 2022Series A$5M
#2
Series B · Sydney, New South Wales · founded 2021 · 1 employees$15.6Mraised▾
Developer of peptide drugs for cardiovascular disorders. It offers a lead compound IB001 which is a potent and selective inhibitor of human ASIC1a that protect neurons and heart muscle cells from ischemic injury.
- Jul 2022Series B$15.6M
#3
Deadpooled · Sydney, New South Wales · founded 2019 · 4 employees$600Kraised▾
Provider of wearable device and app for monitoring body vitals parameters. The company smart device and companion app for users to monitor their blood pressure, heart rate, body composition, sleep, body recovery & movement, and much more.
- Mar 2022Seed$600K
#4
Late Stage · Sydney, New South Wales · founded 1995$55Mraised▾
HeartWare International develops and manufactures small implantable heart pumps or ventricular assist devices for the treatment of advanced heart failure. The company offers HeartWare Ventricular Assist System, which includes a left ventricular assist device, or blood pump, patient accessories, and surgical tools designed to provide circulatory support for patients in the advanced stage of heart failure. It is also developing the Miniaturized Ventricular Assist Device, a miniaturized device intended for chronic heart failure patients. HeartWare International, Inc. sells and markets its products through clinical studies in the United States, as well as directly to cardiac centers and hospitals internationally. The company is headquartered in Framingham, Massachusetts.
- Aug 2009Post IPO$55M
#5
Series A · Melbourne, Victoria · founded 2005 · 30 employees$5.2Mraised▾
The HD medical Group produces stethoscopes with a high-resolution integrated phonocardiogram (PCG) visual display featuring the world’s first murmur indicator. Their stethoscopes have a unique embedded algorithm that enables clinicians to quickly screen for heart anomalies and murmurs. The scope has a tunable filter giving you the ability to select specific parts of the heart sound to listen to, such as S1/S2, S3/S4 murmurs, etc.
- Jan 2019Conventional Debt—
- Jan 2019Series A$4.4M
- Feb 2016Seed$800K
#6
Series A · Melbourne, Victoria · founded 2014$1.5Mraised▾
Semacare, based out of Australia, operates in three business divisions. The company focuses on internet of things. The company's initial product is the Remon Vital Signs monitor, which comprises of the ECG recorder, thermometer, pulse oximeter, sleep monitor, etc. The product offers tele-medicine and emergency services. The product has built-in Bluetooth wireless connectivity, and the vital signs measured can be sent to mobile phone or tablet. The data can be share to a doctor by email, or a record of your ECGs can be maintained to share it during a doctor's appointment. The company's other divisions are distribution and IVD. The IVD division comprises of the CellaVision range and the associated software and APP.
- Jul 2020Series A—
- Feb 2019Seed$1.5M
#7
Public · Pymble, New South Wales · founded 2007 · 15 employees$1.9Mraised▾
Cell based therapies with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. It is a clinical-stage regenerative medicine company developing a portfolio of cell-based therapies with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company has two product candidates in Phase 1 trials for humans: Progenza is an allogeneic off the shelf adipose stem cell therapy to treat osteoarthritis and other musculoskeletal conditions and RGSH4K is an autologous therapeutic cancer vaccine to treat a wide range of cancer types. The company has a stem cell secretions based cream targeting acne and other inflammatory skin conditions. The company has two therapies targeting animal conditions such as CryoShot is a clinical-stage allogeneic off-the-shelf adipose stem cell therapy for the treatment of canine and equine osteoarthritis and other musculoskeletal conditions and Kvax is an autologous therapeutic cancer vaccine in clinical trials.
- Sep 2018Conventional Debt$1.9M
#8
Deadpooled · Melbourne, Victoria · founded 2012 · 15 employees$5Mraised▾
CliniCloud launched Bluetooth-connected stethoscopes and thermometers that enable consumers to check their own vitals and have a doctor access them via the cloud. The CliniCloud medical kit transfers the data of vital to the mobile phone via blue tooth and hooks information from the app up with remote physicians. As of June'2015, ClinicCloud is accepting pre-orders at $109 per kit.
- Sep 2015Seed$5M
#9
Acqui-Hired · Glenelg, South Australia · founded 2011 · 29 employees$580.1Kraised▾
Develops a wearable device for cardiac monitoring. Liba3 is a multi-function 4-1 monitoring device that includes mobile cardiac telemetry, wireless cardiac event, holter, and extended Holter monitoring in a wearable patch. The device comes with hardware, software (cloud-based physician diagnostics and reporting), and a monitoring system. As of Jan'18, Liba is undergoing pre-market review by FDA.
- Jun 2019Seed$580.1K
#10
Funding Raised · Sydney, New South Wales · founded 2007 · 3 employees—raised▾
Endoluminal Sciences is an early stage venture-backed company, developing platform technologies in the space of endovascular prostheses. Immediate focus is the treatment of abdominal aortic aneurysms (AAAs), with future applications across vascular diseases. Technology allows active sealing and fixation of current generation endografts in short and angulated necks.
- 2005Grant (prize money)—
#11
Deadpooled · Melbourne, Victoria · founded 2003—raised▾
Armaron Bio develops small molecule therapeutics for cardiovasular diseases. Its lead candidate targets muscle loss associated caused by myocardial infarctions by preventing excessive apoptosis, and is currently in phase II trials for heart failure. Their lead candidate NP202 (currently in Phase 2 trials) provides cardioprotection from ischaemia-reperfusion injury reducing the activation of p38 MAPK and certain other mechanisms.
- Mar 2004Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.